Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm, Multi-center Phase Ib/IIa Clinical Study to Evaluate the Tolerability, Safety, and Initial Efficacy of T3011 Herpesvirus Injection Combined With PD-1/PD-L1 Inhibitors in Patients With Advanced Solid Tumors

NCT06214143 is registered in ClinicalTrials.gov with Shanghai Pharmaceuticals Holding Co., Ltd as lead sponsor.

NCT NCT06214143
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06214143 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm, Multi-center Phase Ib/IIa Clinical Study to Evaluate the Tolerability, Safety, and Initial Efficacy of T3011 Herpesvirus Injection Combined With PD-1/PD-L1 Inhibitors in Patients With Advanced Solid Tumors
Lead sponsor
Shanghai Pharmaceuticals Holding Co., Ltd
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 11, 2024
Completion date
December 31, 2026
Enrollment
68 (estimated)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors